135 related articles for article (PubMed ID: 38850654)
1. Improvement of daratumumab- or elotuzumab-mediated NK cell activity by the bi-specific 4-1BB agonist, DARPin α-FAPx4-1BB: A preclinical study in multiple myeloma.
Saltarella I; Link A; Lamanuzzi A; Reichen C; Robinson J; Altamura C; Melaccio A; Solimando AG; Ria R; Mariggiò MA; Vacca A; Frassanito MA; Desaphy JF
Biomed Pharmacother; 2024 Jul; 176():116877. PubMed ID: 38850654
[TBL] [Abstract][Full Text] [Related]
2. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.
Balasa B; Yun R; Belmar NA; Fox M; Chao DT; Robbins MD; Starling GC; Rice AG
Cancer Immunol Immunother; 2015 Jan; 64(1):61-73. PubMed ID: 25287778
[TBL] [Abstract][Full Text] [Related]
3. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
[No Abstract] [Full Text] [Related]
4. Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma.
Cho H; Kim KH; Lee H; Kim CG; Chung H; Choi YS; Park SH; Cheong JW; Min YH; Shin EC; Kim JS
Clin Cancer Res; 2021 May; 27(10):2947-2958. PubMed ID: 33602683
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
Campbell KS; Cohen AD; Pazina T
Front Immunol; 2018; 9():2551. PubMed ID: 30455698
[TBL] [Abstract][Full Text] [Related]
6. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.
Collins SM; Bakan CE; Swartzel GD; Hofmeister CC; Efebera YA; Kwon H; Starling GC; Ciarlariello D; Bhaskar S; Briercheck EL; Hughes T; Yu J; Rice A; Benson DM
Cancer Immunol Immunother; 2013 Dec; 62(12):1841-9. PubMed ID: 24162108
[TBL] [Abstract][Full Text] [Related]
7. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.
Mahaweni NM; Bos GMJ; Mitsiades CS; Tilanus MGJ; Wieten L
Cancer Immunol Immunother; 2018 Jun; 67(6):861-872. PubMed ID: 29500635
[TBL] [Abstract][Full Text] [Related]
8. The CD38
Sarkar S; Chauhan SKS; Daly J; Natoni A; Fairfield H; Henderson R; Nolan E; Swan D; Hu J; Reagan MR; O'Dwyer M
Cancer Immunol Immunother; 2020 Mar; 69(3):421-434. PubMed ID: 31919623
[TBL] [Abstract][Full Text] [Related]
9. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
[TBL] [Abstract][Full Text] [Related]
10. 4-1BB engagement costimulates NKT cell activation and exacerbates NKT cell ligand-induced airway hyperresponsiveness and inflammation.
Kim DH; Chang WS; Lee YS; Lee KA; Kim YK; Kwon BS; Kang CY
J Immunol; 2008 Feb; 180(4):2062-8. PubMed ID: 18250411
[TBL] [Abstract][Full Text] [Related]
11. Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.
Pazina T; James AM; Colby KB; Yang Y; Gale A; Jhatakia A; Kearney AY; Graziano RF; Bezman NA; Robbins MD; Cohen AD; Campbell KS
Cancer Immunol Res; 2019 Oct; 7(10):1633-1646. PubMed ID: 31431433
[TBL] [Abstract][Full Text] [Related]
12. Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells.
Panaampon J; Kariya R; Okada S
Cancer Immunol Immunother; 2022 Oct; 71(10):2497-2509. PubMed ID: 35262781
[TBL] [Abstract][Full Text] [Related]
13. 4-1BB agonism: adding the accelerator to cancer immunotherapy.
Chester C; Ambulkar S; Kohrt HE
Cancer Immunol Immunother; 2016 Oct; 65(10):1243-8. PubMed ID: 27034234
[TBL] [Abstract][Full Text] [Related]
14. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
Adams HC; Stevenaert F; Krejcik J; Van der Borght K; Smets T; Bald J; Abraham Y; Ceulemans H; Chiu C; Vanhoof G; Usmani SZ; Plesner T; Lonial S; Nijhof I; Lokhorst HM; Mutis T; van de Donk NWCJ; Sasser AK; Casneuf T
Cytometry A; 2019 Mar; 95(3):279-289. PubMed ID: 30536810
[TBL] [Abstract][Full Text] [Related]
15. CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab.
Soh KT; Tario JD; Hahn T; Hillengass J; McCarthy PL; Wallace PK
Cytometry B Clin Cytom; 2021 Jul; 100(4):497-508. PubMed ID: 33017079
[TBL] [Abstract][Full Text] [Related]
16. CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity.
Stoll A; Bruns H; Fuchs M; Völkl S; Nimmerjahn F; Kunz M; Peipp M; Mackensen A; Mougiakakos D
Leukemia; 2021 Dec; 35(12):3482-3496. PubMed ID: 34021248
[TBL] [Abstract][Full Text] [Related]
17. Targeting CD137 enhances the efficacy of cetuximab.
Kohrt HE; Colevas AD; Houot R; Weiskopf K; Goldstein MJ; Lund P; Mueller A; Sagiv-Barfi I; Marabelle A; Lira R; Troutner E; Richards L; Rajapaska A; Hebb J; Chester C; Waller E; Ostashko A; Weng WK; Chen L; Czerwinski D; Fu YX; Sunwoo J; Levy R
J Clin Invest; 2014 Jun; 124(6):2668-82. PubMed ID: 24837434
[TBL] [Abstract][Full Text] [Related]
18. FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma.
Bigley AB; Spade S; Agha NH; Biswas S; Tang S; Malik MH; Dai L; Masoumi S; Patiño-Escobar B; Hale M; DiPierro G; Martell R; Hann B; Shah N; Wiita AP; Liu X
Blood Adv; 2021 Aug; 5(15):3021-3031. PubMed ID: 34357379
[TBL] [Abstract][Full Text] [Related]
19. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.
Miller RE; Jones J; Le T; Whitmore J; Boiani N; Gliniak B; Lynch DH
J Immunol; 2002 Aug; 169(4):1792-800. PubMed ID: 12165501
[TBL] [Abstract][Full Text] [Related]
20. Synergistic Effects of Venetoclax and Daratumumab on Antibody-Dependent Cell-Mediated Natural Killer Cytotoxicity in Multiple Myeloma.
Nakamura A; Suzuki S; Kanasugi J; Ejiri M; Hanamura I; Ueda R; Seto M; Takami A
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]